Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., LTD
Product carbon footprint report
1.1 Introduction
The problem of global warming and the excessive emission of greenhouse gases may lead to climate change and impact, which has become an important environmental issue and consensus that the world is facing. Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., LTD. (hereinafter referred to as Haiyan Pharmaceutical), based on the environmental concept of sustainable development and fulfilling the obligations of corporate social responsibility, will actively contribute to the inventory and control of greenhouse gas emissions in order to mitigate the resulting global warming, hoping to save energy and resources and maintain the sustainable development of the global ecological environment through the management of the company.
1.2 Company Profile
Company name: Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., LTD
Industry type: Other industries
Scope: After audit, it is confirmed that Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd. has a factory site in Beijing, which is located at No. 16, Life Garden Road, Changping District, Beijing, where the emission unit is located, and there is no emission source outside Beijing.
Company Location: Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd. is located in Changping District, Beijing City, China Life Garden Road No. 16.
Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd. was established in February 2004, located in Zhongguancun Life Science Park. It is the only R&D center and regional headquarters of Yangzijiang Group in northern China, and has built a comprehensive pharmaceutical enterprise integrating drug research and development, production and sales. Driven by innovation and research and development, Beijing Haiyan Pharmaceutical implements the strategy of "simultaneous development of traditional Chinese medicine and chemical medicine", focusing on the product pipeline of respiratory system, cardiovascular system and psychonervous system, relying on the geographical advantages of talents and universities in Beijing and the platform resources of the Group headquarters, and combining its own production, quality management and sales systems. Jointly conduct research on the introduction and industrialization of innovative results. Suhuang cough capsule, Cosu (Irbesartan tablet), Monica (racecadotril tablet), Rizatriptan benzoate tablet and other excellent new varieties have been industrialized. Based on the capital science and technology resources, Beijing Haiyan has increased research and development efforts. At present, 21 projects are under research and 12 patents have been granted, including 11 invention patents. Since 2005, Beijing Haiyan Pharmaceutical has been awarded the National high-tech Enterprise, the Outstanding Growth Enterprise of the G20 Project of Beijing Biomedical Industry Leapfrog Development Project, the Beijing Enterprise Technology Center, and the Beijing Engineering Technology Research
Center, Zhongguancun high-tech enterprise and other honors. Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd. has a professional and strong industrialization team and marketing team. Relying on the sales network of Yangzijiang Pharmaceutical Group all over the country, we will expand the production capacity of our products and bring them to the market, contributing to the people's medical and health cause.
In 2016, the company was awarded the G20 enterprise assessed by the Beijing Science and Technology Commission, the "Beijing Honest Enterprise" certificate issued by the Beijing Pharmaceutical Industry Association, the "Beijing New Technology and New products (services)" issued by the Beijing Science and Technology Commission, and the "Changping Science and Technology Research and Development Center" again assessed by the Beijing Changping Science and Technology Commission. "Science and Technology Innovation Award" issued by China Quality Evaluation Association, "Science and Technology Innovation Award" issued by Beijing Enterprise Evaluation Association, "Beijing Corporate Social Responsibility fulfillment commitment Unit", "National Quality trustworthy Unit" and so on.
Within 3 years, Haiyan Pharmaceutical has passed all drug GMP certification inspections and follow-up inspections organized by drug regulatory departments at all levels
There are no qualified batches in the inspection process. Within 3 years, no illegal advertisements were issued by the drug supervision and administration department to stop the sale of related drugs
Within 5 years, no serious violations of the relevant provisions of drug supervision and administration such as the production and sale of counterfeit drugs have occurred
The incident occurred to the drug supervision and administration department.
Beijing Haiyan has perfect credit management, financial management, quality management, contract management, labor management, safety management, after-sales management system. Strictly abide by the Drug Administration Law, the Implementation Regulations of the Drug Administration Law, the Measures for the Supervision and Administration of Drug Production, the Measures for the Administration of Drug Registration, the Measures for the Supervision and Administration of Drug Circulation, the Measures for the Administration of Drug Recall, the Measures for the Administration of Adverse Drug Reaction Reporting and Monitoring, and other laws and regulations, and engage in related drug production and sales activities in accordance with the law, with no bad records. The company has a sound quality management system, through the ISO 9001, ISO 14001 and OHSAS 18001 system, measurement management system, CNAS certification. In the past 5 years, no serious defects have been found in the GMP certification inspection and follow-up inspection, and the general defects can be rectified in time. The company implements the quality authorization system, implements active management of drug quality and safety after listing, and has established a management system for sales, adverse drug reaction monitoring, complaints, recall, response to sudden drug incidents, etc., with clear responsibilities and sound procedures, and can take effective measures to monitor relevant information.
Haiyan Pharmaceutical applied for 4 new invention patents in 2016, and 2 new authorized invention patents in 2017. Since its establishment, the sales revenue of Beijing Haiyan has continued to grow, exceeding 500 million yuan in 2015. From 2016 to 2017, the sales revenue increased by 17% and the net profit increased by 33%, making it the fastest growing subsidiary within Yangzijiang Pharmaceutical Group. Beijing Haiyan strives to improve the quality system, accelerate the transformation and upgrading of enterprises, vigorously promote Six Sigma management, meet international standards in quality management level, and take the initiative to improve the management of standard FDA.
In 2018, the company achieved operating income of 9915.98 billion yuan, net profit of 158.68 million yuan, output value of 991.498 million yuan, and consumption of all kinds of energy 1,807.03 tons of standard coal.
Home